Clorox (NYSE:CLX – Get Free Report) had its target price boosted by equities research analysts at Morgan Stanley from $125.00 to $136.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 15.57% from the company’s current price.
Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price objective on shares of Clorox from $114.00 to $117.00 and gave the stock a “neutral” rating in a report on Wednesday. Citigroup raised their price target on shares of Clorox from $109.00 to $115.00 and gave the stock a “neutral” rating in a research note on Wednesday. Rothschild & Co Redburn dropped their price objective on Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Barclays reissued an “underweight” rating and issued a $109.00 target price on shares of Clorox in a research report on Friday, January 16th. Finally, Evercore ISI dropped their price target on Clorox from $132.00 to $115.00 and set an “underperform” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $117.73.
Read Our Latest Stock Report on Clorox
Clorox Price Performance
Clorox (NYSE:CLX – Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.04). The business had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a return on equity of 299.67% and a net margin of 11.17%.The firm’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.55 EPS. On average, equities analysts anticipate that Clorox will post 7.15 EPS for the current year.
Insider Buying and Selling at Clorox
In other news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the acquisition, the director owned 13,000 shares in the company, valued at $1,353,690. This represents a 44.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.63% of the stock is currently owned by corporate insiders.
Institutional Trading of Clorox
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Center for Financial Planning Inc. bought a new position in Clorox in the 3rd quarter valued at $25,000. Vermillion & White Wealth Management Group LLC bought a new stake in Clorox during the third quarter valued at $25,000. Total Investment Management Inc. bought a new stake in Clorox during the second quarter valued at $25,000. True Wealth Design LLC grew its position in Clorox by 1,020.0% during the third quarter. True Wealth Design LLC now owns 224 shares of the company’s stock worth $28,000 after buying an additional 204 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in Clorox by 567.6% in the 2nd quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock worth $27,000 after acquiring an additional 193 shares during the last quarter. Institutional investors own 78.53% of the company’s stock.
Key Headlines Impacting Clorox
Here are the key news stories impacting Clorox this week:
- Positive Sentiment: Management reaffirmed the company’s 2026 outlook and reported revenue roughly in line/above consensus, which calmed some investor concerns about guidance stability. Clorox Posts Mixed Q2 Results, Reaffirms 2026 Outlook
- Positive Sentiment: Cash flow metrics cited in coverage showed improvement (operating cash increased versus prior year), which supports dividend coverage and buyback flexibility. Clorox Company (CLX) Stock Falls on Q2 2026 Earnings
- Neutral Sentiment: Clorox said it is weighing a potential GOJO acquisition and finishing its ERP integration — both are strategic moves that could boost long‑term scale but create near‑term execution and cost uncertainty. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
- Neutral Sentiment: Management will present at the upcoming CAGNY conference (Feb. 19); investors can expect more detail on integration progress and M&A plans there. Clorox to Present at 2026 CAGNY Conference
- Negative Sentiment: EPS missed Street estimates (adjusted EPS below consensus) and organic sales declined year‑over‑year, reflecting softer demand and shoppers trading down — a direct near‑term headwind for margins. Clorox Q2 Earnings Miss Estimates, Lower Organic Sales Hurt
- Negative Sentiment: Several analysts adjusted price targets and ratings after the print (some cuts and one sizable downgrade), increasing near‑term sell‑side uncertainty. Deutsche Bank adjusts Clorox price target to $112
Clorox Company Profile
The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.
Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.
Featured Stories
- Five stocks we like better than Clorox
- The day the gold market broke
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Trump Planning to Use Public Law 63-43: Prepare Now
- What a Former CIA Agent Knows About the Coming Collapse
- Forget AI, This Will Be the Next Big Tech Breakthrough
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
